SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Acquisition

29 Aug 2006 07:01

Tristel PLC29 August 2006 For release29 August 2006 Tristel Plc Technology Acquisition Agreement with IVC Limited, New Zealand Tristel plc ("Tristel"), the chlorine dioxide specialist that supplies infectionand contamination control products to healthcare and institutionalestablishments and the pharmaceutical and food processing industries, announcesthat it has entered into a technology acquisition agreement with IVC Limited, ("IVC"). IVC is Tristel's New Zealand distributor and its principal shareholderis Mark Fraundorfer, an internationally renowned Urologist. Under the terms of the agreement IVC transfers to Tristel the design and patentrights to two inventions which it has created to work specifically withTristel's chlorine dioxide chemistry. The inventions are a sterilizing traysystem which enables single use decontamination of endoscopic equipment and ahygiene work station which enables Tristel's highly effective sporicidalchemistry to be easily applied to floors and walls in high risk wards anddepartments of hospitals. IVC has funded the design and development process to date and transfers theintellectual property created in return for unspecified future royalties. Commenting upon the agreement, Paul Swinney, Chief Executive of Tristel, said: "Outside of the most advanced healthcare markets, where endoscopes are mainlyprocessed in sophisticated and costly automated machines, the majority ofendoscopes are disinfected in basic trays and sinks. These can only holddisinfectant liquids that have to be used repeatedly for many instruments over aperiod of many hours or even days. "The Tristel tray system, combined with Tristel's novel burstable sachet,Tristel Fusion, enables the disinfectant to be used once and to be dedicated toone instrument only. "This achieves one of the key features of the most sophisticated endoscopereprocessing machines at a fraction of their cost, and will help Tristelpenetrate many overseas markets with its chlorine dioxide disinfectants." Tristel plc Parkgreen Communications Ltd Paul Swinney, Chief Executive Paul McManusPaul Barnes, Finance Director Tel 020 7493 3716Tel: 01638 721 500 Mob: 07980 541 893http://www.tristel.com paul.mcmanus@parkgreenmedia.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Mar 20188:19 amRNSIssue of Equity
26th Mar 20187:00 amRNSCommercial collaboration with Parker Laboratories
8th Mar 201810:58 amRNSIssue of Equity
20th Feb 20187:00 amRNSHalf-year Report
8th Feb 20182:19 pmRNSHolding(s) in Company
26th Jan 20187:00 amRNSIssue of Equity
24th Jan 20187:00 amRNSStudy shows comparable efficacy of Tristel Wipes
17th Jan 20187:00 amRNSInvestor results presentation
12th Dec 20172:57 pmRNSResult of AGM
12th Dec 20177:00 amRNSAGM Statement & notice of results
27th Nov 201710:35 amRNSIssue of Equity
23rd Nov 20173:24 pmRNSClarification of AGM timing
14th Nov 201710:34 amRNSIssue of Equity
2nd Nov 20177:00 amRNSDirectors dealing/grant of options
23rd Oct 20174:41 pmRNSIssue of Equity
19th Oct 20177:01 amRNSDirector Appointment
19th Oct 20177:00 amRNSFinal Results
3rd Oct 20177:00 amRNSTiming of EPA approval
19th Sep 20177:00 amRNSInvestor results presentation
18th Sep 20171:44 pmRNSIssue of Equity
22nd Aug 201712:08 pmRNSIssue of Equity
18th Aug 20171:31 pmRNSDirector/PDMR Dealing - replacement
17th Aug 20177:00 amRNSDirector/PDMR Dealing
7th Aug 20172:29 pmRNSIssue of Equity
24th Jul 20179:46 amRNSIssue of Equity
19th Jul 20177:00 amRNSTrading update & Notice of results
5th Jul 20177:00 amRNSIssue of Equity
3rd Jul 20171:59 pmRNSStrategic investment
3rd Jul 20177:00 amRNSSubmission to EPA & subsidiary incorporated in USA
13th Jun 20177:00 amRNSIssue of Equity
24th May 20177:00 amRNSShareholder Open Day & Notice of Trading Update
19th May 20173:34 pmRNSIssue of Equity
3rd May 20178:27 amRNSIssue of Equity
7th Apr 20175:04 pmRNSResult of Placing
7th Apr 20172:07 pmRNSProposed Secondary Placing
28th Mar 20172:38 pmRNSIssue of Equity
7th Mar 20179:41 amRNSIssue of Equity
6th Mar 20177:00 amRNSIssue of Equity
27th Feb 20177:00 amRNSProducts approved by Australia's TGA
27th Feb 20177:00 amRNSJournal of Ultrasound in Medicine & Biology
23rd Feb 20177:00 amRNSHalf-year Report
25th Jan 20177:00 amRNSInvestor results presentation
24th Jan 20177:00 amRNSJournal of Infection Prevention: TSTL wipes study
17th Jan 201712:31 pmRNSDirector / PDMR Shareholding
13th Dec 201612:30 pmRNSResult of AGM
13th Dec 20167:00 amRNSAGM Statement
6th Dec 20167:00 amRNSIssue of Equity
28th Nov 20163:42 pmRNSNotice of AGM correction
23rd Nov 201612:37 pmRNSIssue of Equity
17th Oct 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.